文献速递皮肤肿瘤

Vismodegib治疗德国局部晚期基底细胞癌真实世界研究NIELS:有效性、安全性与使用情况

Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-05-27

NIELS非干预研究在德国26个中心观察了66例局部晚期基底细胞癌患者接受vismodegib治疗的情况。客观缓解率为74.2%,疾病控制率为90.9%,中位缓解持续时间为15.9个月(95%CI 9.2;25.7),中位无进展生存期为19.1个月,中位至缓解时间为2.7个月。63例(95.5%)患者报告340例不良事件,未发现新安全性信号。

要点

  • vismodegib在真实世界中治疗局部晚期基底细胞癌客观缓解率74.2%、疾病控制率90.9%
  • 中位缓解持续时间15.9个月,中位无进展生存期19.1个月,中位至缓解时间2.7个月
  • 95.5%患者报告不良事件,未发现新安全性信号

核心结论

  • NIELS研究显示vismodegib在局部晚期基底细胞癌患者中具有有效性和安全性,证实关键试验结果可转化至常规临床实践。

研究设计与样本

  • 非干预研究(NIS)观察德国临床实践中按德国标签使用vismodegib治疗局部晚期基底细胞癌的情况。
  • 纳入2013年8月2日至2016年3月31日前至少接受一剂vismodegib的所有可用患者,回顾性和/或前瞻性记录长达3年。
  • 2015年9月至2019年3月在26个德国中心观察66例患者,主要有效性变量为缓解持续时间(DOR),肿瘤缓解由治疗医师评估,统计分析均为描述性。

主要发现

  • 客观缓解率(ORR)为74.2%,疾病控制率(DCR)为90.9%。
  • 中位缓解持续时间(DOR)为15.9个月(95%CI:9.2;25.7;n=49例缓解患者)。
  • 中位无进展生存期(PFS)为19.1个月,中位至缓解时间(TTR)为2.7个月。
  • 63例(95.5%)患者报告340例不良事件,未发现新安全性信号。

关键数值与推荐

  • 客观缓解率74.2%,疾病控制率90.9%。
  • 中位缓解持续时间15.9个月(95%CI:9.2;25.7;n=49例缓解患者)。
  • 中位无进展生存期19.1个月,中位至缓解时间2.7个月。
  • 63例(95.5%)患者报告340例不良事件。

临床怎么用

  • vismodegib可用于不适合手术或放疗的局部晚期基底细胞癌患者的真实世界治疗。
  • 治疗期间应监测不良事件,本研究未发现新安全性信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Basal cell carcinoma (BCC) can arise by the uncontrolled proliferation of cells from multiple epidermal compartments due to aberrant activation of the Hedgehog (Hh) signalling pathway. Vismodegib, a small-molecule inhibitor of this pathway, is approved for treatment of patients with locally advanced (la) BCC inappropriate for surgery or radiotherapy or patients with symptomatic metastatic (m) BCC. OBJECTIVES: The aim of this non-interventional study was to assess effectiveness with a special focus on duration of response (DOR), safety and utilization of vismodegib for treatment of laBCC in daily practice in Germany. METHODS: This non-interventional study (NIS) observed treatment of laBCC with vismodegib according to the German label in clinical practice. All available patients who had received at least one dose of vismodegib between commercial availability of vismodegib in Germany (02 August 2013) and 3 years before end of study (31 March 2016) could be included and were documented retrospectively and/or prospectively for up to 3 years. Primary effectiveness variable was DOR. Assessment of tumour response was carried out by the treating physicians. Exploratory variables included utilization of vismodegib, decision makers for therapy and method of tumour response evaluation. All statistical analyses were descriptive. RESULTS: Between September 2015 and March 2019, 66 patients were observed at 26 German centres. The objective response rate (ORR) was 74.2% and the disease control rate (DCR) was 90.9%. The median DOR was 15.9 months (95% CI: 9.2; 25.7; n = 49 patients with response). The median progression-free survival (PFS) was 19.1 months and the median time to response (TTR) 2.7 months. A total of 340 adverse events were reported in 63 (95.5%) patients; no new safety signals were identified. CONCLUSIONS: The NIS NIELS shows effectiveness and safety of vismodegib in patients with laBCC. It confirms the transferability of the results of the pivotal trial into routine clinical practice.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gutzmer R, Schulze HJ, Hauschild A, et al. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS. J Eur Acad Dermatol Venereol. 2021. PMID: 33931910. doi:10.1111/jdv.17332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。